Multiple Sclerosis Therapy Receives New Funding
- Multiple Sclerosis (MS) is a chronic,often debilitating disease that affects teh central nervous system - the brain and spinal cord.
- Current MS treatments primarily focus on slowing disease activity and managing symptoms like fatigue, vision problems, and mobility issues. Though, they don't address the existing nerve damage.
- The therapy targets a process called excitotoxicity, where excessive stimulation of nerve cells leads to their damage and death.
“`html
New Therapy Shows Promise in Halting Multiple sclerosis Progression and Repairing Nerve Damage
What is Multiple Sclerosis?
Multiple Sclerosis (MS) is a chronic,often debilitating disease that affects teh central nervous system - the brain and spinal cord. Worldwide, approximately 2.8 million people live with MS, facing a range of symptoms that disrupt daily life. The disease occurs when the immune system mistakenly attacks myelin, the protective sheath surrounding nerve fibers, hindering communication between the brain and body.
The Promise of a Regenerative Approach
Current MS treatments primarily focus on slowing disease activity and managing symptoms like fatigue, vision problems, and mobility issues. Though, they don’t address the existing nerve damage. This new therapy, spearheaded by Dr. Fang Liu at CAMH,offers a fundamentally different approach: regeneration. It aims to not only halt the progression of MS but also actively repair the damage already done.
The therapy targets a process called excitotoxicity, where excessive stimulation of nerve cells leads to their damage and death. By selectively blocking excitotoxicity *without* disrupting normal brain function, the treatment encourages the body’s natural ability to rebuild myelin and improve nerve recovery. Preclinical studies in animal models have demonstrated significant restoration of motor skills and myelin repair, even when the treatment was initiated after symptoms appeared.
How Does the Therapy Work?
excitotoxicity plays a crucial role in the pathology of MS. When nerve cells are overstimulated, they release excessive amounts of glutamate, a neurotransmitter. This overstimulation leads to calcium influx, triggering a cascade of events that ultimately damage or kill the nerve cell. The therapy developed by Dr. Liu’s team aims to modulate this process, preventing the damaging effects of excitotoxicity while preserving normal neuronal signaling.
The compound’s ability to restore function even *after* symptom onset is particularly noteworthy. This suggests a potential for reversing existing disability, a goal that has remained elusive in MS treatment. The team’s success in animal models provides a strong rationale for moving forward with human clinical trials.
Funding and collaboration
The project has received substantial funding totaling nearly $800,000 USD ($1,137,868 CAD) from Brain Canada, the National MS Society’s fast Forward program, and Health Canada through the canada Brain Research Fund. This collaborative effort highlights the importance of investing in innovative research to address complex neurological disorders.
The research team is a transatlantic partnership, led by Dr.Fang Liu, Senior Scientist at CAMH and professor in the Department of Psychiatry at the University of Toronto, and Dr. Iain Greig, Reader in Medicinal Chemistry at the University of Aberdeen. This collaboration brings together expertise in neuroscience, medicinal chemistry, and clinical translation.
Looking Ahead: Clinical Trials and Potential Impact
The research team is currently in the final stages of preclinical testing, meticulously preparing for future human clinical trials. If these trials are successful, this therapy coudl represent Canada’s first regenerative treatment for MS, offering hope for improved outcomes and quality of life for individuals living with the disease.